Erratum: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group (Journal of Clinical Oncology (2025) DOI: 10.1200/JCO-24-01841)

The article by Huang et al titled "Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group"(J Clin Oncol 10.1200/JCO-24-01841) was published June 10, 2025, with errors. In the section "Impact of HSCT on Outcomes in the High-Risk Disease Groups,"the second sentence of the second paragraph read, "DFS was 16.9% (95% CI, 4.3 to 36.7) compared with 50.9% (95% CI, 32.7 to 66.5; P = .032), and CIR was 74.3% (95% CI, 47.2 to 88.9) compared with 37.0 (95% CI, 20.5 to 53.5; P = .025; Fig 3; Table 2)."It should have read, "DFS was 16.9% (95% CI, 4.3 to 36.7) compared with 50.9% (95% CI, 32.7 to 66.5; P = .032), and CIR was 74.3% (95% CI, 47.2 to 88.9) compared with 37.0% (95% CI, 20.5 to 53.5; P = .025; Fig 3; Table 2)."In Figure 2, in the lower left box, the sample size for "CM Low-risk"read "(n = 20)"but should have read "(n = 636)."In Table 1: • Under CM SR MRD+ ○ In the column "Chemo in CR1 (n = 39), No. (%)"▪ In the bottom group of rows labeled "MRD at end of induction I"• The value for the row labeled "Negative"read "39 (100)."It should have read "0."• The value for the row labeled "Positive"read "0."It should have read "39 (100)."○ In the column "HSCT in CR1 (n = 33), No. (%)"▪ In the bottom group of rows labeled "MRD at end of induction I"• The value for the row labeled "Negative"read "33 (100)."It should have read "0."• The value for the row labeled "Positive"read "0."It should have read "33 (100)."This has been corrected as of July 14, 2025. Journal of Clinical Oncology and the authors apologize for the errors.